Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study

World Journal of Urology

Volumn 35, Issue 4, 2017, Pages 595-603

  Timilshina, Narhari ^a   Ouellet, Veronique ^c   Alibhai, Shabbir M H ^a   Mes Masson, Anne Marie ^c   Delvoye, Nathalie ^c   Drachenberg, Darrel ^f   Finelli, Antonio ^a   Jammal, Marie Paule ^e   Karakiewicz, Pierre ^b,c   Lapointe, Hélène ^f   Lattouf, Jean Baptiste ^b,c   Lynch, Kenny ^g   Paradis, Jean Benoît ^d   Sitarik, Paula ^f   So, Alan ^g   Saad, Fred ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Institut du Cancer de Montreal   (Canada)

^d Gouvernement du Quebec   (Canada)

^e Centre de Sante et de Services Sociaux de Laval   (Canada)

^f Manitoba Prostate Centre   (Canada)

^g Vancouver Prostate Center   (Canada)

Author keywords

Active surveillance; Population based study; Prostate cancer; Treatment

Indexed keywords

ADULT; AGE; AGED; CANADA; CANCER GRADING; CLINICAL TRIAL; DISEASE MANAGEMENT; HUMAN; LARGE CORE NEEDLE BIOPSY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; UTILIZATION; VERY ELDERLY; WATCHFUL WAITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY, LARGE-CORE NEEDLE; CANADA; DISEASE MANAGEMENT; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; ODDS RATIO; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; WATCHFUL WAITING;

EID: 84979234423     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-016-1897-0     Document Type: Article

References (24)

1. Canadian Cancer Statistics (2015) Ottawa (ON): Statistics Canada. www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2015-EN.pdf. Accessed may 2015
2. Bray F, Lorten-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eng J Cancer 46(17):3040–3052
3. Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
4. Cooperberg MR, Broering JM, Kantoff PW et al (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19
5. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213
6. Dall’Era MA, Albertsen PC, Bangma C et al (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 63:976–983
7. Dragomir A, Cury FL, Aprikian AG (2014) Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open 2(2):E60–E68
8. Alibhai SMH, Breunis H, Timilshina N et al (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with non-metastatic prostate cancer. J Clin Oncol 28:5038–5045
9. Loeb S, Bjurlin MA, Nicholson J, Tammela TL et al (2014) Ovediagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055
10. Abdollah F, Sun M, Schmitges J et al (2012) Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol 188(1):73–83
11. Klotz L, Vesprini D, Sethukavalan P et al (2015) Long term follow up of large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277
12. Matthew Andrews J, Ashfield JE, Morese M et al (2014) Five-year follow up of active surveillance for prostate cancer: a Canadian community-based urological experience. Can Urol Assoc J 8(11–12):E768–E774
13. Stattin P, Holmberg E, Johansson JE et al (2010) Outcomes in localized prostate cancer: National Prostate Cancer registers of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958
14. Filson CP, Chroeck FR, Ye Z et al (2014) Variation in use of active surveillance among men undergoing expectant management for early state prostate cancer. J Urol 192:75–80
15. Mohler J, Armstrong A, Bahnson R et al (2012) Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:1081–1087
16. Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383
17. Cristea O, Lavallee LT, Montroy J et al (2016) Active surveillance in Canadian men with low-grade prostate cancer. CMAJ 188(8):E141–E147
18. Maurice MJ, Abouassaly R, Kim SP, Zhu H (2015) Contemporary nationwide patterns of active surveillance use for prostate cancer. JAMA Intern Med 175(9):1569–1571
19. Loeb S, Folkvaljon, Makarov DV et al (2015) Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol 67(2):238
20. Womble PR, Montie JE, Ye Z et al (2015) Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67(1):44–50
21. Loeb S, Berglund A, Stattin P (2013) Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 190(5):1742–1749
22. Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669–3676
23. Weerakoon M, Papa N, Lawrentschuk N et al (2015) The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian prostate cancer registry. BJU Int 115(suppl 5):50–56
24. Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M (2014) Prostate cancer: summary of updated NICE guidance. BMJ 348:f7524